
==== Front
Z Gastroenterol
Z Gastroenterol
10.1055/s-00000094
Z Gastroenterol
Zeitschrift Fur Gastroenterologie
0044-2771
1439-7803
Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

38917831
10.1055/a-2300-0375
zgastro-2023-12-0195-CR
Kasuistik
Remission of refractory esophageal lichen planus induced by tofacitinib
Remission eines refraktären Lichen planus im Ösophagus durch TofacitinibBieneck Valentina Dr.
http://orcid.org/0000-0001-6413-8816
Decker Annegrit Dr.
http://orcid.org/0000-0001-5082-7979
Schmitt-Graeff Annette Prof.
http://orcid.org/0000-0001-6884-0135
Kreisel Wolfgang Prof.
http://orcid.org/0000-0001-5147-0123
Schauer Franziska Dr.
1 88751 Department of Dermatology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
2 88751 Department of Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, Medical Center, University of Freiburg, Freiburg, Germany
3 88751 University of Freiburg Faculty of Medicine, Freiburg, Germany
Correspondence Prof. Wolfgang Kreisel 88751 Department of Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, Medical Center, University of Freiburg FreiburgGermanywolfgang.kreisel@uniklinik-freiburg.de
25 6 2024
9 2024
1 6 2024
62 9 13841388
18 12 2023
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
2024
The Author(s).
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.

As of now, there exists no established therapy for ELP. Retinoids, which are standard in treating cutaneous LP, do not exhibit positive effects in ELP. While topical glucocorticosteroids often yield favorable responses in esophageal inflammation, some cases prove recalcitrant or refractory. In such instances, various immunosuppressive therapies have been attempted with variable success.

This report details a severe case of ELP that showed resistance to prednisolone, acitretin, alitretinoin, adalimumab, tacrolimus, hydroxychloroquine plus mycophenolate mofetil, and cyclophosphamide. The initiation of the JAK inhibitor tofacitinib induced an impressive clinical, endoscopic, and histological remission. This positive response to a JAK inhibitor is discussed in the context of our evolving understanding of the immune-mediated pathogenesis of this disease.

Zusammenfassung

Eine Beteiligung des Ösophagus (ELP) ist eine selten diagnostizierte Manifestation eines Lichen planus, einer gut bekannten, wahrscheinlich autoimmun-vermittelten Hauterkrankung. In den letzten Jahren wurden Kriterien zur Diagnose vorgestellt: Bei der Endoskopie sieht man eine Schleimhautablösung, ein Einreißen der Schleimhaut, eine Trachealisierung ähnlich wie bei der eosinophilen Ösophagitis. Die Histologie zeigt eine bandförmige Infiltration mit T-Lymphozyten im Bereich der Basalmembran mit Übergreifen in das Epithelium und einer Ablösung der Schleimhaut, Apoptosen der Epithelzellen, und eine Hyperkeratose, auf deren Boden sich ein Plattenepithel-Karzinom entwickeln kann. Führendes klinisches Symptom ist eine Dysphagie. Symptomfreie Verläufe kommen vor, aber auch Fälle mit oberer gastrointestinaler Blutung. Eine etablierte Therapie des ELP gibt es noch nicht. Meist spricht die Erkrankung auf topische Kortikosteroide an. In schweren Fällen wurden verschiedene immunsuppressive Therapien angewandt.

Wir beschreiben eine Patientin mit einem schweren ELP, die auf eine Therapie mit topischen oder systemischen Kortikosteroiden, Acitretin, Alitretinoin, Adalimumab, Tacrolimus, Hydroxychloroquin kombiniert mit Mycophenolatmofetil und Cylophosphamid nicht oder kaum ansprach. Nach Gabe des JAK-Inhibitors Tofacitinib kam es zu einer eindrucksvollen klinischen, endoskopischen und histologischen Remission. Wir diskutieren diesen positiven Effekt eines JAK-Inhibitors bei einem ELP in Zusammenhang mit neuen Erkenntnissen über die Immunpathogenese des Lichen planus.

Keywords

lichen planus
JAK-inhibitor
esophagus
autoimmunity
dermatology
mucosal detachment
endoscopy
Schlüsselwörter

Lichen ruber
JAK Inhibitor
Ösophagus
Autoimmunität
Dermatologie
Mucosale Spaltbildung
Endoskopie
==== Body
pmcIntroduction

Lichen planus (LP) is a common mucocutaneous disorder affecting 0.5 to 2.0% of the general population with a notable female predominance 1 2 . Its manifestations primarily involve the skin, oral, and genital mucosa, with additional occurrences in the nails, scalp, eyes, ears, urinary bladder, and nasal mucosa 3 . Esophageal lichen planus (ELP), while described in case reports and a few case series, has only recently been characterized by reproducible clinical, endoscopic, and histopathological features 4 5 6 7 8 9 10 11 . Predominantly found in middle-aged women, ELP typically presents with dysphagia as the primary symptom 4 5 6 7 8 9 10 11 . The spectrum of symptoms varies from asymptomatic cases to mild or severe dysphagia and, in rare instances, to upper gastrointestinal bleeding 10 . ELP should be considered in cases of esophageal bolus obstruction 12 . If left untreated, ELP can progress to squamous cell esophageal carcinoma 13 14 .

For LP, clinical guidelines recommend topical glucocorticosteroids, retinoids, or cyclosporin 15 16 . In severe or unresponsive cases, a range of interventions has been attempted, including intralesional of systemic glucocorticosteroids, calcineurin inhibitors, sulphasalazine, azathioprine, hydroxychloroquine, methotrexate, mycophenolate mofetil, or TNF inhibitors.

Endoscopically, ELP exhibits mucosal denudation, tearing, and a ring-like appearance of the esophagus, referred to as “trachealization”, resembling the trachea. Prolonged courses may lead to hyperkeratosis and scarring stenosis. Histopathological features include lymphoid inflammatory infiltrates at the interphase between the lamina propria and epithelium associated with mucosal detachment, T-cell spillover into the epithelium, apoptotic squamous cells (Civatte bodies), epidermoid metaplasia, and hyperkeratotic lesions with low- or high-grade dysplasia as a risk factor for invasive squamous cell carcinoma. Despite numerous interventions, there is no established therapy for ELP 10 . Applying the same therapy as for “classical” LP may be successful in most cases. However, refractory courses present a challenge for dermatologists and gastroenterologists. Surprisingly, retinoids, which are part of the standard repertoire of therapy for cutaneous LP, have neither prevented the occurrence of ELP nor reduced its severity 8 .

This case report details a patient with severe, progressive, and treatment-resistant ELP unresponsive to nine therapies: topical rather than systemic. Ultimately, tofacitinib, targeting JAK1 and JAK3, induces a remarkable clinical, endoscopic, and histologic remission.

Case report

A 56-year-old female patient sought care at the gastroenterology and dermatology outpatient clinics, presenting with a constellation of complex symptoms. These included retrosternal pain, dysphagia, and a persistent cough, notably exacerbating by the ingestion of solid food. Additionally, she reported on severe itching of the scalp followed by scarring alopecia and painful burning of the oral and genital mucosa. She had a prior diagnosis of monoclonal gammopathy of undetermined significance and arterial hypertension.

An initial investigation included an external esophagogastroduodenoscopy (EGD), which revealed “oesophagitis of unknown origin”. Subsequent histological examination of an esophageal mucosal biopsy initially prompted suspicion of mucous membrane pemphigoid as the probable diagnosis. Clinically, the patient exhibited erosive mucosal lesions in the oral and genital regions, along with erythematous papules on the scalp, indicative of lichen planopilaris.

Immunological diagnostics, encompassing direct and indirect immunofluorescence, and serological testing for bullous pemphigoid antibodies via ELISA, as well as immunoblotting, yielded negative or no evidence of autoimmune blistering diseases. A repeated EGD and histopathological evaluation now supported the diagnosis of lichen planus affecting multiple sides and the esophagus.

The treatment approach began with a variety of intensive topical therapies. These included application of mometasonfuorate solution to the scalp and tacrolimus 0.1% ointment for the genital mucosa. Encouragingly, these localized interventions showed positive responses. Oral budesonide gel 0.5 mg BID was tried for treatment of the esophagus 8 .

Nevertheless, esophageal symptoms such as dysphagia, retrosternal burning, and tussive irritation showed no improvement. Over the course of almost nine years, alongside topical budesonide, we pursued various systemic interventions. These included prednisolone, acitretin, alitretinoin, adalimumab, tacrolimus, hydroxychloroquine combined with mycophenolate mofetil, and cyclophosphamide (administered in 10 cycles of 750 mg each).

Unfortunately, the majority of these treatments exhibited limited success. Although there were intermittent improvements in oral and genital mucosal lesions and scalp conditions, EGDs consistently revealed persistently active severe ELP , as depicted in Fig. 1 A, marked by extensive spontaneous mucosal sloughing and tearing. Histological examinations consistently displayed the full-blown characteristics of severe ELP, as illustrated in Fig. 2 A.

Fig. 1 Endoscopic aspect of the esophagus. A Before start of tofacitinib. The typical aspect of severe ELP is seen: mucosal sloughing, tearing, and trachealization. B Six months after start of tofacitinib: mucosal sloughing is still visible. A distal stenosis has developed. C Twelve months after start of tofacitinib: marked reduction in mucosal fragility. D Fifteen months after start of tofacitinib: no mucosal denudation. No spontaneous tearing. The trachealization is still present. The distal stenosis has abated.

Fig. 2 Histologic features of esophageal biopsies before initiating ( A, B ) and after 15 months of ( C, D ) tofacitinib treatment. A Dense band-like inflammatory infiltrate of the tunica propria spilling over to the squamous epithelium associated with an extended suprabasal epithelial detachment. B CD3+ T-cells (red) are the predominant cellular component of the sub- and intraepithelial inflammatory reaction. C, D Achievement of clinical improvement is highlighted by marked reduction in inflammation with residual intraepithelial T-cells (brown). Here, the apparent epithelial detachment represents an artefact due to specimen processing. A, C hematoxylin and eosin stain; B, D immunolabeling using a monoclonal anti-CD3 antibody and a red ( B ) or brown substrate ( D ). Original magnification: A x 10, B x 63, C, D x 40.

Seven dilations to 12 mm were required to address the esophageal stenosis that gradually developed in the distal third of the esophagus. Eight years after first diagnosis of ELP a critical incident of food impaction occurred, necessitating an emergency procedure for bolus removal. Notably, only the cyclophosphamide treatment cycles provided temporary relief of dysphagia symptoms, with improved swallowing for approximately six months. Unfortunately, we were unable to continue cyclophosphamide therapy due to cumulative toxic hematologic effects and the lack of effect on skin.

After having stopped cyclophosphamide we initiated tofacitinib therapy. It was only when the full dose of 11 mg daily was reached that the esophageal symptoms began to improve. Despite the macroscopic findings six months after initiating tofacitinib ( Fig. 1 B) not yet displaying clear changes compared to findings before ( Fig. 1 A), a subsequent endoscopy twelve months on tofacitinib ( Fig. 1 C) revealed significant improvement. The spontaneous mucosal denudation had notably decreased, although the distal stenosis remained visible, aligning with the patient’s symptoms.

The latest endoscopic aspect after fifteen months of treatment is depicted in Fig. 1 D: there was no longer spontaneous mucosal sloughing, indicating tight adherence of the mucosa to the submucosa. Only minimal tearing could be seen as an artificial lesion by the endoscope. Notably, the distal stenosis has completely abated. The only remaining characteristic was the marked trachealization of the esophageal wall. Histopathological examination confirmed the macroscopic changes: no mucosal detachment was evident, and the intra- and subepithelial lymphocyte count had normalized. Hyperkeratotic lesions were absent. Fig. 2 allows a comparison between the characteristic histologic feature of the esophageal mucosa in biopsies obtained before the start of tofacitinib (A,B) and after 15 months of tofacitinib treatment (C,D), highlighting the excellent therapeutic response.

At the patient’s most recent assessments 15 and 22 months under tofacitinib, she reported no more restrictions on food intake. This therapeutic approach has led to a notable enhancement in the patient’s overall well-being, marked by weight gain and recovery of her appetite.

Discussion

Esophageal involvement in LP is an underdiagnosed and underreported manifestation of this common manifold skin disorder. At present, the prevalence of ELP is still unknown. Preliminary data suggest that ELP might be more prevalent than another emerging inflammatory esophageal disease, e.g., eosinophilic esophagitis. Therefore, further research is necessary to determine the true prevalence of ELP. Given the different therapeutic responses of cutaneous and esophageal LP to standard therapy, this suggests possible differences in their underlying pathogenesis.

The immune response in potential immune-mediated skin diseases may be classified into six response patterns 17 . Studies on the composition of the cellular components of the lichenoid infiltrates revealed type-1 lymphocytes (Tc1-cells, Th1 cells, ILC1, NKT, and NK) as the predominant population with reaction to exogenous or self-altered antigens presented by APCs, DCs, or keratinocytes. The Th1-inflammatory response with secretion of proinflammatory cytokines, such as IL-23, IL-17, and IFN-γ, and secretion of the cytotoxic molecules perforin, granulysin, and granzym B seem to promote the main pathogenetic events. After binding to its receptor, IFN-γ activates JAK1 and JAK2 and activates STAT 18 in keratinocytes and infiltrating lymphocytes, mainly STAT-1 19 20 . Other authors rather demonstrated JAK2 activation in lymphocytes and STAT-1 activation in keratinocytes in active LP lesions 21 22 . These data form a rational basis for the use of JAK inhibitors in LP (and in other skin diseases with similar pathogenesis such as psoriasis) 23 . Consequently, several studies confirmed that JAK inhibitors may be a pathogenesis-based rational approach to control LP, particularly in recalcitrant cases, when classical therapy fails 24 25 . A recent review summarized the outcomes of patients with LP treated with a JAK inhibitor, encompassing the literature up to October 2022 26 . In the tofacitinib group (JAK1/3), 21 out of 30 patients experienced either complete or partial resolution of the lesions. For baricitinib (JAK1/2), the responding figure was 9 out of 16, for ruxolitinib (JAK1/2) 12 out of 12, and for upatacitinib (JAK1) 2 out of 2. Meanwhile, several JAK inhibitors gained FDA approval for dermatological indications 27 . The current data, comprising case reports and small case series of patients with LP, lacks clear guidance on the preferred choice among available JAK inhibitors. However, targeting JAK1 may be a crucial factor for a successful outcome.

After several futile attempts to control the disease in this patient, we chose to apply the JAK1/3 inhibitor tofacitinib. Additionally, in the present cooperation between dermatology and gastroenterology, we favored this JAK inhibitor in analogy to the therapy of another gastroenterological disease, ulcerative colitis. Interestingly, the initial dose of 5 mg OD had only a very moderate effect. It was only the dose of 10 mg (or 11 mg) daily that showed efficacy, corresponding to published data applied in LP patients and in autoimmune bullous diseases 26 28 . In ulcerative colitis, 10 mg BID is recommended for induction therapy, while the maintenance dose for this disease is 5 mg BID 29 30 31 32 .

The present case is interesting in several aspects: 1. it expands our knowledge on the treatment of ELP, an area where information is currently limited; 2. the present manuscript adds further data to the scant literature that demonstrates a positive response of a recalcitrant ELP to a JAK inhibitor 33 34 ; 3. the use of tofacitinib resulted in a robust macroscopic and histologic response. The esophageal stenosis nearly completely resolved, and clinical symptoms, including dysphagia and retrosternal discomfort, nearly disappeared. This underscores the potential efficacy of JAK inhibitors in managing challenging cases of ELP. Reports such as the present one aim to stimulate further investigations into this intersection of immunological diseases where dermatology and gastroenterology meet.

Conflict of Interest FS was funded by the Berta-Ottenstein-Programme for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg. The authors declare that they have no conflict of interest.
==== Refs
References

1 González-Moles MÁ Warnakulasuriya S González-Ruiz I Worldwide prevalence of oral lichen planus: A systematic review and meta-analysis Oral Dis 2021 27 813 828 10.1111/odi.13323 32144836
2 Li C Tang X Zheng X Global Prevalence and Incidence Estimates of Oral Lichen Planus: A Systematic Review and Meta-analysis JAMA Dermatol 2020 156 172 181 10.1001/jamadermatol.2019.3797 31895418
3 Le Cleach L Chosidow O Clinical practice. Lichen planus N Engl J Med 2012 366 723 732 10.1056/NEJMcp1103641 22356325
4 Harewood GC Murray JA Cameron AJ Esophageal lichen planus: the Mayo Clinic experience Dis Esophagus 1999 12 309 311 10.1046/j.1442-2050.1999.00073.x 10770369
5 Quispel R van Boxel OS Schipper ME High prevalence of esophageal involvement in lichen planus: a study using magnification chromoendoscopy Endoscopy 2009 41 187 193 10.1055/s-0028-1119590 19280529
6 Katzka DA Smyrk TC Bruce AJ Variations in presentations of esophageal involvement in lichen planus Clin Gastroenterol Hepatol 2010 8 777 782 10.1016/j.cgh.2010.04.024 20471494
7 Kern JS Technau-Hafsi K Schwacha H Esophageal involvement is frequent in lichen planus: study in 32 patients with suggestion of clinicopathologic diagnostic criteria and therapeutic implications European Journal of Gastroenterology & Hepatology 2016 28 1374 1382 10.1097/MEG.0000000000000732 27580215
8 Schauer F Monasterio C Technau-Hafsi K Esophageal lichen planus: towards diagnosis of an underdiagnosed disease Scandinavian Journal of Gastroenterology 2019 54 1189 1198 10.1080/00365521.2019.1674375 31608788
9 Monasterio C Decker A Schauer F Der Lichen planus des Ösophagus – Eine unterschätzte Erkrankung Z Gastroenterol 2021 59 460 469 10.1055/a-1378-9380 33831967
10 Decker A Schauer F Lazaro A Esophageal lichen planus: Current knowledge, challenges and future perspectives World J Gastroenterol 2022 28 5893 5909 10.3748/wjg.v28.i41.5893 36405107
11 Jacobs JW Kukreja K Camisa C Demystifying Esophageal Lichen Planus: A Comprehensive Review of a Rare Disease You Will See in Practice Am J Gastroenterol 2022 117 70 77 10.14309/ajg.0000000000001485 34591036
12 Sengupta N Tapper EB Corban C The clinical predictors of aetiology and complications among 173 patients presenting to the Emergency Department with oesophageal food bolus impaction from 2004–2014 Aliment Pharmacol Ther 2015 42 91 98 10.1111/apt.13237 25963885
13 Bombeccari GP Pallotti F Guzzi G Oral-esophageal lichen planus associated with oral squamous cell carcinoma Indian J Dermatol Venereol Leprol 2008 74 509 511 10.4103/0378-6323.44323 19052424
14 Ravi K Codipilly DC Sunjaya D Esophageal Lichen Planus Is Associated With a Significant Increase in Risk of Squamous Cell Carcinoma Clin Gastroenterol Hepatol 2019 17 1902 19030 10.1016/j.cgh.2018.10.018 30342260
15 Ioannides D Vakirlis E Kemeny L European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology J Eur Acad Dermatol Venereol 2020 34 1403 1414 10.1111/jdv.16464 32678513
16 Solimani F Forchhammer S Schloegl A Lichen planus – a clinical guide JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2021 19 864 882 10.1111/ddg.14565
17 Eyerich K Eyerich S Immune response patterns in non-communicable inflammatory skin diseases J Eur Acad Dermatol Venereol 2018 32 692 703 10.1111/jdv.14673 29114938
18 Barrat FJ Crow MK Ivashkiv LB Interferon target-gene expression and epigenomic signatures in health and disease Nat Immunol 2019 20 1574 1583 10.1038/s41590-019-0466-2 31745335
19 Damsky W King BA JAK inhibitors in dermatology: the promise of a new drug class J Am Acad Dermatol 2017 76 736 744 10.1016/j.jaad.2016.12.005 28139263
20 Damsky W Wang A Olamiju B Treatment of severe lichen planus with the JAK inhibitor tofacitinib J Allergy Clin Immunol 2020 145 1708 171000 10.1016/j.jaci.2020.01.031 32018031
21 Shao S Tsoi LC Sarkar MK IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus Sci Transl Med 2019 11 eaav7561 10.1126/scitranslmed.aav7561 31554739
22 Brumfiel CM Patel MH Severson KJ Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study J Invest Dermatol 2022 142 2109 2.116E7 10.1016/j.jid.2022.01.015 35131254
23 Solimani F Meier K Ghoreschi K Emerging Topical and Systemic JAK Inhibitors in Dermatology Front Immunol 2019 10 2847 10.3389/fimmu.2019.02847 31849996
24 Didona D Caposiena Caro RD Sequeira Santos AM Therapeutic strategies for oral lichen planus: State of the art and new insights Front Med (Lausanne) 2022 9 997190 10.3389/fmed.2022.997190 36267615
25 Vičić M Hlača N Kaštelan M Comprehensive Insight into Lichen Planus Immunopathogenesis Int J Mol Sci 2023 24 3038 10.3390/ijms24033038 36769361
26 Abduelmula A Bagit A Mufti A The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review J Cutan Med Surg 2023 27 271 276 10.1177/12034754231156100 36815857
27 Aihie O Dyer JA JAK Inhibitors: A New Weapon in the Skin Care Providers’ Arsenal Mo Med 2023 120 45 48 36860609
28 Huang D Zhang Y Kong L Janus kinase inhibitors in autoimmune bullous diseases Front Immunol 2023 14 1.220887E6 10.3389/fimmu.2023.1220887
29 Mpakogiannis K Fousekis FS Christodoulou DK The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review Dig Liver Dis 2023 55 1311 1317 10.1016/j.dld.2023.05.021 37316363
30 Macaluso FS D’Antonio E Fries W Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study Dig Liver Dis 2023 10.1016/j.dld.2023.08.061
31 Tursi A Mocci G Cingolani L Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study Expert Opin Pharmacother 2023 24 1649 1656 10.1080/14656566.2023.2230126 37358928
32 Irving PM Leung Y Dubinsky MC Review article: guide to tofacitinib dosing in patients with ulcerative colitis Aliment Pharmacol Ther 2022 56 1131 1145 10.1111/apt.17185 35993338
33 Kooybaran NR Petzold G Schön MP Esophageal lichen planus successfully treated with the JAK1/3 inhibitor tofacitinib J Dtsch Dermatol Ges 2022 20 858 860 10.1111/ddg.14762
34 Kozlov M Levit EK Silvers DN Severe Esophageal Lichen Planus Treated With Tofacitinib Cutis 2023 111 155 163 10.12788/cutis.0717 37224491
